BOSTON – Treatment with latanoprostene bunod 0.024% induced a significant increase in optic nerve blood volume and oxygen saturation compared with latanoprost 0.005%, according to a presentation at the American Academy of Optometry annual meeting.
“Prostaglandin analogues are generally regarded as medical standard of care for glaucomatous optic neuropathy,”
Dan Samaha, OD, MSc, FAAO, from the Montreal University of Optometry, said during an academy-sponsored press conference. “As of 2021, IOP remain the only modifiable risk factor. There is undeniable evidence that blood flow dysregulation plays a major role in the pathogenesis of glaucomatous optic neuropathy.”
To evaluate the effect of Vyzulta (latanoprostene bunod 0.024%, Bausch + Lomb), Samaha and colleagues recruited 23 healthy participants ages 21 to 62 years into a prospective double-blind crossover study.
The researchers measured optic nerve head capillary blood volume (ONHvol) and oxygen saturation (ONHSaO2) at baseline and over a period of 2 hours. They then remeasured after a 7-day once-daily treatment with either latanoprostene bunod or Xalatan (latanoprost 0.005%, Pfizer).
After 30 days, Samaha and colleagues had the participants crossed over to the alternative product and repeated the ONHvol and ONHSaO2 measurements.
Latanoprostene bunod 0.024% increased ONHSaO2 by 4% compared with latanoprost (
P < .001).
Latanoprostene bunod 0.024% increased ONHvol by more than twofold at 1 hour (
P < .001), 90 minutes (
P < .001) and 2 hours (
P = .023), which was 66.2% higher than latanoprost 0.005% at 1 hour (
P < .001), 47% higher at 90 minutes (
P = .007) and 45% higher at 2 hours (
P = .02).
“Based on these improvements, future studies are underway to evaluate whether similar responses are elicited in patients suffering from glaucomatous optic neuropathy,” Samaha said.
Vyzulta significantly improves optic nerve blood volume
